Anti-Human NGcGM3 Recombinant Antibody (Racotumomab)
CAT#: TAB-H58
Recombinant Mouse antibody to Human NGcGM3. Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Published Data
Inhib
Figure 1 Antitumor protection against spontaneous lung nodule formation by immunization with racotumomab-alum.
Mice were inoculated subcutaneously with 3LL cells and immunized with racotumomab-alum at a dose of 50 μg, as described in "Materials and Methods." Subcutaneous primary tumor growth.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Inhib
Figure 2 Effects of racotumomab-alum immunization and chemotherapy on spontaneous lung nodule formation.
Mice were inoculated subcutaneously with 3LL cells, and then immunized with racotumomab-alum (raco-alum) at 50 μg/dose and/or administered with pemetrexed (100 mg/kg).
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Agonist
Figure 3 NeuGc-specific humoral response elicited by racotumomab-alum vaccination.
Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Flow cytometric analysis.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Agonist
Figure 4 Racotumomab-alum induces NeuGc-specific humoral response.
Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Percent of recognized X63 cells.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Cyt
Figure 5 Immune response induced in racotumomab/alum-vaccinated patients.
Survival of patients with cytotoxic antibodies killing 30% or more (red line) L1210 cells versus patients with less than 30% lysis (blue line).
Hernández, A. M., & Vázquez, A. M. (2015). Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer. Expert review of vaccines, 14(1), 9-20.
ELISA
Figure 6 Maximal titers of anti-racotumomab and anti-NeuGc-GM3 antibody responses for all evaluable patients in each dose level.
Specificity controls are shown as empty circles (mouse IgG1 isotype control) and empty lozenges (NeuAc-GM3 ganglioside).
Cacciavillano, W., Sampor, C., Venier, C., Gabri, M. R., de Dávila, M. T., Galluzzo, M. L., ... & Chantada, G. L. (2015). A Phase I Study of the Anti‐Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatric blood & cancer, 62(12), 2120-2124.
❮
❯
Specifications
- Host Species
- Mouse
- Derivation
- Mouse
- Type
- IgG1 - kappa
- Specificity
- idiotope of anti-(N-glycolylneuraminic acid (NeuGc, NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3 [Homo sapiens]
- Species Reactivity
- Human
- Applications
- Inhib, Agonist, Cyt, ELISA
- Trade name
- vaxira
- CAS
- 946832-34-4
- Generic Name
- racotumomab
- UNII
- 52G405U1E5
- MW
- 146,133.55 g/mol
- Related Disease
- Breast cancers
Product Property
- Purity
- >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
Applications
- Application Notes
- The Human NGcGM3 antibody has been reported in applications of Inhibition, Agonist, Cytotoxicity, Enzyme-linked Immunosorbent Assay.
Inhib: 50 μg.
Agonist: 50 μg/dose.
Target
- Alternative Names
- racotumomab;vaxira;946832-34-4;1E10;N-glycolil (NGc) GM3;NGcGM3;NGNA ganglioside
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for TAB-H58. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Biosimilar Overview
Please refer to Racotumomab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Racotumomab.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Racotumomab"
Afuco™ Anti-NGCGM3 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H58)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Mouse antibody to Human NGcGM3. It is a therapeutic cancer vaccine for the treatment of solid tumors. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
DrugMonitor™ Anti-Racotumomab Antibody (VS-1224-YC972)Racotumomab is a form of active immunotherapy designed to stimulate the immune system to recognize and combat cancer cells. It has been used in trials for treating glioma, Wilms' tumor, neuroblastoma, retinoblastoma, and Ewing's sarcoma. The DrugMonitor™ Anti-Racotumomab Antibody (VS-1224-YC972) is an anti-drug antibody (ADA) against Racotumomab. This drug-based antibody is raised in mice immunized with the Racotumomab. The anti-Racotumomab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Racotumomab in samples.
See other products for "NGcGM3"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABL-663 | Human Anti-NGCGM3 Recombinant Antibody (clone chP3) | ELISA | Chimeric (mouse/human) IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBL-657 | Human Anti-NGCGM3 Recombinant Antibody (clone chP3); Fab Fragment | ELISA | Chimeric (mouse/human) Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PSBL-657 | Mouse Anti-NGCGM3 Recombinant Antibody (clone chP3); scFv Fragment | ELISA | Mouse scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-H58 | Afuco™ Anti-NGCGM3 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H58) | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: WB, ELISA, FC, IHC, IF, IP
Application: FC, IHC, Cyt, FuncS
Application: Neut, FuncS, IHC, ELISA, FC, Inhib
Application: ELISA, Neut, FuncS
Application: ELISA, Inhib, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
